The American Journal of Medicine
Volume 121, Issue 7 , Pages 555-561, July 2008

Update on Fibromyalgia Therapy

  • Micha Abeles, MD

      Affiliations

    • Division of Rheumatology, Department of Medicine, The University of Connecticut School of Medicine, Farmington
  • ,
  • Bruce M. Solitar, MD

      Affiliations

    • Division of Rheumatology, Department of Medicine, New York University School of Medicine/NYU Hospital for Joint Diseases, New York
    • New York Harbor VA Healthcare System, New York Campus; New York.
  • ,
  • Michael H. Pillinger, MD

      Affiliations

    • Division of Rheumatology, Department of Medicine, New York University School of Medicine/NYU Hospital for Joint Diseases, New York
    • New York Harbor VA Healthcare System, New York Campus; New York.
  • ,
  • Aryeh M. Abeles

      Affiliations

    • Division of Rheumatology, Department of Medicine, The University of Connecticut School of Medicine, Farmington
    • Division of Rheumatology, Department of Medicine, New York University School of Medicine/NYU Hospital for Joint Diseases, New York
    • New York Harbor VA Healthcare System, New York Campus; New York.
    • Corresponding Author InformationRequests for reprints should be addressed to Aryeh M. Abeles, MD, New England Musculoskeletal Institute, Medical Arts & Research Building, UConn Health Center, 263 Farmington Avenue, Farmington, CT 06030-5352.

Abstract 

Primary fibromyalgia, a poorly-understood chronic pain syndrome, is characterized by widespread musculoskeletal pain, nonrestorative sleep, fatigue, psychological distress, and specific regions of localized tenderness, all in the absence of otherwise apparent organic disease. While the etiology of fibromyalgia is unclear, accumulating data suggest that disordered central pain processing likely plays a role in the pathogenesis of symptoms. Although various pharmacological treatments have been studied and espoused for treating fibromyalgia, no single drug or group of drugs has proved to be particularly useful in treating fibromyalgia patients as a whole, and only one drug to date has earned U.S. Food and Drug Administration approval for treating the syndrome in the United States. This review critically and systematically evaluates clinical investigations of medicinal and nonmedicinal treatments for fibromyalgia dating from 1970 to 2007.

Keywords: Complementary therapy, Fibromyalgia, Fibrositis, Pharmacotherapy

 

PII: S0002-9343(08)00264-7

doi:10.1016/j.amjmed.2008.02.036

The American Journal of Medicine
Volume 121, Issue 7 , Pages 555-561, July 2008